HYPAQUE-CYSTO Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Hypaque-cysto, and when can generic versions of Hypaque-cysto launch?
Hypaque-cysto is a drug marketed by Ge Healthcare and is included in one NDA.
The generic ingredient in HYPAQUE-CYSTO is diatrizoate meglumine. There are eleven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the diatrizoate meglumine profile page.
Summary for HYPAQUE-CYSTO
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 32 |
Clinical Trials: | 4 |
Patent Applications: | 890 |
Formulation / Manufacturing: | see details |
DailyMed Link: | HYPAQUE-CYSTO at DailyMed |
Recent Clinical Trials for HYPAQUE-CYSTO
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Institute of Liver and Biliary Sciences, India | N/A |
Cephalon | Phase 2 |
Dartmouth-Hitchcock Medical Center | Phase 2 |
US Patents and Regulatory Information for HYPAQUE-CYSTO
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ge Healthcare | HYPAQUE-CYSTO | diatrizoate meglumine | SOLUTION;URETHRAL | 016403-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |